Clinical Trials
131 trialsAD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma
University of Florida
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
St. Jude Children's Research Hospital
PHITT
University of Birmingham
Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib
Memorial Sloan Kettering Cancer Center
Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer
Roswell Park Cancer Institute
A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective
Thomas Jefferson University
CCGLC-001
Tongji Hospital
Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC
Humanity & Health Medical Group Limited
Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer
University of California, San Francisco
Sorafenib Plus Hepatic Arterial Infusion Versus Sorafenib for HCC with Major Portal Vein Tumor Thrombosis
Peking University
SELECT
Air Force Military Medical University, China
Clinical Pharmacogenetic Study of Sorafenib in Egyptian Patients With Hepatocellular Carcinoma
Assiut University
HAIC Plus Sorafenib Versus TACE Plus Sorafenibfor Advanced HCC
Sun Yat-sen University
TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC
Sichuan Cancer Hospital and Research Institute
CCGLC-008
Tongji Hospital
Sorafenib In Egyptian Patients With Hepatocellular Carcinoma.
Damanhour University
Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer
Jonsson Comprehensive Cancer Center
HAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized Trial
Sun Yat-sen University
Phase â…¡ Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACE
Sun Yat-sen University
Microvascular Invasion for Guiding Treatment of Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma
Sun Yat-sen University
SBRT+TACE+Sorafenib Vs Sorafenib in the Treatment of uHCC With PVTT
First Affiliated Hospital of Zhejiang University
TACE+Tilelizumab+Sorafenib in the Treatment of BCLC Stage C HCC
First Affiliated Hospital of Zhejiang University
MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma
Big Ten Cancer Research Consortium
Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
Roswell Park Cancer Institute
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Alliance for Clinical Trials in Oncology
Effect and Safety of Recombinant Human Adenovirus Type 5 in Advanced HCC With Stable Disease After Sorafenib Treatment
First Affiliated Hospital Xi'an Jiaotong University
Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
M.D. Anderson Cancer Center
The Efficacy and Safety of HAIC With FOLFOX vs Sorafenib for Patients Who Showed TACE-resistant: a Retrospective Study
Sun Yat-sen University
Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma
Yale University
HCC
Loma Linda University
Sorafenib-RT in Treating Hepatocellular Carcinoma (SHEP)
University Health Network, Toronto
Lenvatinib Plus TACE Versus Sorafenib Plus TACE for HCC With PVTT
Beijing Ditan Hospital
Toripalimab
Shanghai Zhongshan Hospital
Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma
New Mexico Cancer Research Alliance
Circulating Tumor Cells and Tumor DNA in HCC and NET
University of Aarhus
Study of Enzalutamide With and Without Sorafenib in Advanced Hepatocellular Carcinoma Patients
Memorial Sloan Kettering Cancer Center
Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1
Zhejiang University
DEB-TACE Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular Carcinoma
Guangxi Medical University
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
City of Hope Medical Center
Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil/Leucovorin Versus Sorafenib in Advanced Hepatocellular Carcinoma
Sun Yat-sen University
Sorafenib and LBH589 in Hepatocellular Carcinoma (HCC)
University of Erlangen-Nürnberg Medical School
Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
University of California, San Francisco
Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer
University of Texas Southwestern Medical Center
DKN-01 Inhibition in Advanced Liver Cancer
Johannes Gutenberg University Mainz
Factors Affecting Post-treatment Outcomes in Patients With Hepatocellular Carcinoma
Sohag University
HCC-CTPerf
Centre Hospitalier Universitaire, Amiens
Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Study of SECOX Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (HCC)
The University of Hong Kong
SECOX as Neoadjuvant Therapy in Patients With Locally Advanced HCC
The University of Hong Kong
Sorafenib Tosylate With or Without Pravastatin in Treating Patients With Liver Cancer and Cirrhosis
Federation Francophone de Cancerologie Digestive